perphenazine has been researched along with Chronic Disease in 41 studies
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
Excerpt | Relevance | Reference |
---|---|---|
"Patients with DSM-IV-defined schizophrenia (N = 1,460) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of 4 second-generation drugs (olanzapine, quetiapine, risperidone, or ziprasidone) and followed for up to 18 months (phase 1)." | 9.15 | Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. ( Addington, DE; Davis, SM; Lieberman, JA; McEvoy, JP; Mohamed, S; Rosenheck, RA; Stroup, TS; Swartz, MS, 2011) |
" Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)." | 9.12 | Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006) |
"Patients with schizophrenia (N=1,493) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of four second-generation drugs (olanzapine, quetia-pine, risperidone, or ziprasidone) and followed for up to 18 months." | 9.12 | Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. ( Davis, SM; Hsiao, JK; Keefe, RS; Leslie, DL; Lieberman, J; Lin, H; McEvoy, J; Miller, EA; Perkins, DO; Rosenheck, RA; Sindelar, J; Stroup, TS; Swartz, M, 2006) |
"Subjects with schizophrenia (N=114) who had been randomly assigned to and then discontinued perphenazine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were reassigned randomly to double-blinded treatment with olanzapine, 7." | 9.12 | Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. ( Belz, I; Capuano, GA; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007) |
"Seventeen patients with acute schizophrenia and 30 with chronic schizophrenia were included in a randomized, double-blind parallel-group trial comparing sulpiride and perphenazine." | 9.06 | Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. ( Gordin, A; Koskinen, T; Lepola, U; Rimón, R; Salo, H, 1989) |
"The efficacy of timiperone in schizophrenia as compared with perphenazine was assessed in a double-blind fashion in 205 patients throughout a 12-week treatment period." | 9.05 | Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study. ( Asada, S; Inanaga, K; Nakano, S; Otsuki, S; Samejima, K; Sarai, K; Takahashi, R, 1982) |
"Perphenazine was noninferior to all three SGAs during 18 months of intention-to-treat analysis and in several subanalyses." | 6.79 | Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. ( Lin, H; Rosenheck, R, 2014) |
"Patients with DSM-IV-defined schizophrenia (N = 1,460) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of 4 second-generation drugs (olanzapine, quetiapine, risperidone, or ziprasidone) and followed for up to 18 months (phase 1)." | 5.15 | Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. ( Addington, DE; Davis, SM; Lieberman, JA; McEvoy, JP; Mohamed, S; Rosenheck, RA; Stroup, TS; Swartz, MS, 2011) |
"Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment." | 5.13 | The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. ( Canive, JM; Davis, SM; Hsiao, JK; Khan, A; Lieberman, JA; McEvoy, JP; McGee, M; Miller, DD; Reimherr, F; Stroup, TS; Swanson, JW; Swartz, MS; Wagner, HR, 2008) |
" Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)." | 5.12 | Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006) |
"Patients with schizophrenia (N=1,493) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of four second-generation drugs (olanzapine, quetia-pine, risperidone, or ziprasidone) and followed for up to 18 months." | 5.12 | Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. ( Davis, SM; Hsiao, JK; Keefe, RS; Leslie, DL; Lieberman, J; Lin, H; McEvoy, J; Miller, EA; Perkins, DO; Rosenheck, RA; Sindelar, J; Stroup, TS; Swartz, M, 2006) |
"Subjects with schizophrenia (N=114) who had been randomly assigned to and then discontinued perphenazine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were reassigned randomly to double-blinded treatment with olanzapine, 7." | 5.12 | Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. ( Belz, I; Capuano, GA; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007) |
"Seventeen patients with acute schizophrenia and 30 with chronic schizophrenia were included in a randomized, double-blind parallel-group trial comparing sulpiride and perphenazine." | 5.06 | Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. ( Gordin, A; Koskinen, T; Lepola, U; Rimón, R; Salo, H, 1989) |
"The efficacy of timiperone in schizophrenia as compared with perphenazine was assessed in a double-blind fashion in 205 patients throughout a 12-week treatment period." | 5.05 | Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study. ( Asada, S; Inanaga, K; Nakano, S; Otsuki, S; Samejima, K; Sarai, K; Takahashi, R, 1982) |
"Perphenazine was noninferior to all three SGAs during 18 months of intention-to-treat analysis and in several subanalyses." | 2.79 | Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. ( Lin, H; Rosenheck, R, 2014) |
" The average daily dosage was 81." | 2.64 | Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial. ( Fensbo, C; Fruensgaard, K; Hansen, KM; Sihm, F; Wollenberg, J, 1978) |
"Chronic mood disorders were also assessed using RDC criteria." | 1.26 | Chronic mood disorders in depressed outpatient--diagnosis and response to pharmacotherapy. ( Prusoff, BA; Rounsaville, BJ; Sholomskas, D, 1980) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 27 (65.85) | 18.7374 |
1990's | 2 (4.88) | 18.2507 |
2000's | 8 (19.51) | 29.6817 |
2010's | 4 (9.76) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Rosenheck, R | 1 |
Lin, H | 3 |
Mohamed, S | 2 |
Rosenheck, RA | 7 |
Swartz, M | 2 |
McEvoy, J | 2 |
Stroup, S | 1 |
Fusar-Poli, RR | 1 |
Stroup, TS | 8 |
Lieberman, JA | 7 |
McEvoy, JP | 6 |
Davis, SM | 7 |
Swartz, MS | 6 |
Keefe, RS | 5 |
Miller, AL | 2 |
Hsiao, JK | 6 |
Addington, DE | 1 |
HOMBURGER, F | 1 |
BARBOUR, JP | 1 |
PETERSEN, PB | 1 |
Perkins, DO | 3 |
Davis, CE | 1 |
Lebowitz, BD | 1 |
Severe, J | 1 |
Glick, ID | 1 |
Shkedy, Z | 1 |
Schreiner, A | 1 |
Leslie, DL | 1 |
Sindelar, J | 1 |
Miller, EA | 1 |
Lieberman, J | 1 |
Capuano, G | 1 |
Reimherr, F | 2 |
McGee, MF | 1 |
Capuano, GA | 1 |
Belz, I | 1 |
Wagner, HR | 1 |
Swanson, JW | 1 |
Miller, DD | 1 |
McGee, M | 1 |
Khan, A | 1 |
Canive, JM | 1 |
Takahashi, R | 2 |
Inanaga, K | 1 |
Samejima, K | 1 |
Sarai, K | 1 |
Asada, S | 1 |
Otsuki, S | 1 |
Nakano, S | 1 |
Rounsaville, BJ | 1 |
Sholomskas, D | 1 |
Prusoff, BA | 2 |
Ahlfors, UG | 1 |
Dencker, SJ | 1 |
Gravem, A | 1 |
Remvig, J | 2 |
Larsen, EB | 1 |
Gerlach, J | 2 |
Davis, JM | 1 |
Gosenfeld, L | 1 |
Tsai, CC | 1 |
Obukhov, GA | 1 |
Fruensgaard, K | 1 |
Wollenberg, J | 1 |
Hansen, KM | 1 |
Fensbo, C | 1 |
Sihm, F | 1 |
Williams, DH | 1 |
Weissman, MM | 1 |
Astrachan, BM | 1 |
Tegeler, J | 1 |
Floru, L | 1 |
Kistrup, K | 1 |
Aaes-Jørgensen, T | 1 |
Larsen, NE | 1 |
Lepola, U | 1 |
Koskinen, T | 1 |
Rimón, R | 1 |
Salo, H | 1 |
Gordin, A | 1 |
St Jean, A | 1 |
Sterlin, C | 1 |
Noe, W | 1 |
Ban, TA | 1 |
Prien, RF | 1 |
Gillis, RD | 1 |
Caffey, EM | 1 |
Kramer, JC | 1 |
Collins, AD | 1 |
Dundas, J | 1 |
Affleck, JW | 1 |
Cooper, AJ | 1 |
Forrest, AD | 1 |
Smythies, JR | 1 |
Zealley, AK | 1 |
Becker, RE | 1 |
Kellam, AM | 1 |
Jones, KS | 1 |
Uno, M | 1 |
Petersson, H | 1 |
Sorensen, B | 1 |
Akimoto, H | 1 |
Shimazaki, T | 1 |
Shibata, N | 1 |
Sato, Y | 1 |
Yaryura-Tobias, JA | 1 |
Wolpert, A | 1 |
Dana, L | 1 |
Merlis, S | 1 |
Kampman, R | 1 |
Leppäluoto, V | 1 |
Rappaport, M | 1 |
Brophy, JJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
Relative Effectiveness of Schizophrenia Therapy (REST) Study[NCT01245348] | 1,110 participants (Actual) | Observational | 2010-12-31 | Completed | |||
Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain[NCT05001399] | 60 participants (Actual) | Interventional | 2021-10-25 | Completed | |||
Clinical Utility of Pharmacogenomics of Psychotropic Medications[NCT03907124] | Phase 4 | 0 participants (Actual) | Interventional | 2019-06-03 | Withdrawn (stopped due to PI left institution prior to recruitment.) | ||
A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication[NCT02624167] | Phase 2 | 90 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670] | 10,347 participants (Actual) | Interventional | 2016-01-20 | Completed | |||
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia[NCT01623713] | Phase 2 | 260 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis[NCT04368039] | 20 participants (Anticipated) | Interventional | 2019-12-04 | Recruiting | |||
E-SMART: Examining Strategy Monitoring and Remediation Training for Schizophrenia[NCT04756388] | 90 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | |||
Virtual Cognitive Behavioural Therapy for Psychosis: A Randomized Controlled Trial[NCT04752449] | 60 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | |||
Effects of Adding Transcranial Direct Current Stimulation to Executive Function Training for Schizophrenia-spectrum Disorders - a Randomized Control Trial[NCT05389345] | 40 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT01844700)
Timeframe: baseline to week 12
Intervention | percentage of weight change (Mean) |
---|---|
Ziprasidone | 11.58 |
Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
Intervention | BMI percentile (Mean) | |
---|---|---|
baseline | week 12 (n=1, n=2) | |
Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
Intervention | BMI z-score (Mean) | |
---|---|---|
baseline | week 12 (n=1, n=2) | |
Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
Intervention | lbs (Mean) | |
---|---|---|
baseline | week 12 (n=1,2) | |
Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
Ziprasidone | 120.5 | 151 |
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
Intervention | standardized T-score (Mean) | |
---|---|---|
placebo | amphetamine | |
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
Intervention | % inhibition of startle (Mean) | |
---|---|---|
Placebo | Amphetamine | |
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
Intervention | msec (Mean) | |
---|---|---|
placebo | amphetamine | |
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit
Intervention | percentage of annual rate of change (Number) |
---|---|
Prioritized Clinical Decision Support | 14.2 |
Usual Care | 20.8 |
1 review available for perphenazine and Chronic Disease
Article | Year |
---|---|
Maintenance antipsychotic drugs do prevent relapse: a reply to Tobias and MacDonald.
Topics: Antipsychotic Agents; Chlorpromazine; Chronic Disease; Drug Evaluation; Fluphenazine; Humans; Perphe | 1976 |
24 trials available for perphenazine and Chronic Disease
Article | Year |
---|---|
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Drug Admini | 2014 |
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbi | 2015 |
Results of phase 3 of the CATIE schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Cloza | 2009 |
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Comorbidity; Depression; Depressive | 2011 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Clopenthixol; Double-Blind Method; Female; Haloperidol; Human | 2006 |
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; F | 2006 |
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; F | 2006 |
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; F | 2006 |
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; F | 2006 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2007 |
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Dibenzothiazepines; Doub | 2008 |
Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Butyrophenones; Chronic Disease; Clinical Trials as Topic; | 1982 |
Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Clopenthixol; Delayed-Action Preparations; D | 1980 |
Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Dibenzoxazepines; | 1978 |
Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Amitriptyline; Blood Pressure; Body Weight; Chronic Diseas | 1979 |
Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Meth | 1989 |
Clinical studies with propericiazine (R.P. 8909).
Topics: Acute Disease; Adolescent; Adult; Aged; Association; Behavior; Chlorpromazine; Chronic Disease; Clin | 1967 |
Butaperazine (Repoise).
Topics: Chronic Disease; Clinical Trials as Topic; Haloperidol; Humans; Perphenazine; Phenothiazines; Pipera | 1968 |
Intermittent pharmacotherapy in chronic schizophrenia.
Topics: Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Costs and Cost Analysis; Hospitals, Veter | 1973 |
Treatment of chronic hallucinations with diazepam and phenothiazines.
Topics: Adult; Auditory Perception; Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Diazepam; Fem | 1967 |
A double-blind trial of amitriptyline/perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics.
Topics: Adult; Affect; Amitriptyline; Analysis of Variance; Body Weight; Chronic Disease; Clinical Trials as | 1967 |
Penicillamine and schizophrenia--a clinical trial.
Topics: Acute Disease; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Humans; Male; Middle | 1969 |
Evaluation of an amitriptyline-perphenazine combination in chronic schizophrenia.
Topics: Adult; Aged; Amitriptyline; Chronic Disease; Clinical Trials as Topic; Female; Humans; Middle Aged; | 1970 |
A double blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy.
Topics: Age Factors; Chronic Disease; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Hospita | 1971 |
Current status of pharmacotherapy in schizophrenia.
Topics: Adult; Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Humans; Methotrimeprazine; Middle | 1966 |
16 other studies available for perphenazine and Chronic Disease
Article | Year |
---|---|
Clinical experiences and clinical trials.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dyskinesia, Drug-Induced; Humans; Olanzapine | 2008 |
The NIMH-CATIE Schizophrenia Study: what did we learn?
Topics: Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Drug Substitution; Humans; | 2011 |
Perphenazine as an antiemetic agent in cancer and other chronic diseases.
Topics: Antiemetics; Chronic Disease; Neoplasms; Perphenazine; Phenothiazines; Vomiting | 1958 |
Maintenance therapy of chronic psychotics with perphenazine.
Topics: Chronic Disease; Humans; Mental Disorders; Perphenazine; Psychotic Disorders | 1963 |
[WITHDRAWAL OF PSYCHOPHARMACA AND RELAPSE IN SCHIZOPHRENICS].
Topics: Chlorprothixene; Chronic Disease; Humans; Paranoid Disorders; Perphenazine; Recurrence; Schizophreni | 1964 |
Chronic mood disorders in depressed outpatient--diagnosis and response to pharmacotherapy.
Topics: Adolescent; Adult; Affective Symptoms; Amitriptyline; Chronic Disease; Cyclothymic Disorder; Depress | 1980 |
Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Clopenthixol; Delayed-Action Preparations; Dyski | 1996 |
[Prolonged action neuroleptics (review of the foreign literature)].
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Child; Chronic Diseas | 1975 |
[A comparative study of the longacting neuroleptics perphenazin-enanthate and fluspirilene (author's transl)].
Topics: Chronic Disease; Delayed-Action Preparations; Fluspirilene; Humans; Perphenazine; Psychiatric Status | 1979 |
Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Female; Flupenthixol; Humans; Male; Middle | 1991 |
[Follow-up studies of schizophrenia].
Topics: Adult; Catalepsy; Catatonia; Chlorpromazine; Chronic Disease; Convulsive Therapy; Depersonalization; | 1971 |
[Chronic schizophrenia treated with depot perphenazine].
Topics: Adult; Chronic Disease; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male | 1971 |
Action of L-Dopa in drug induced extrapyramidalism.
Topics: Adult; Chlorpromazine; Chronic Disease; Dihydroxyphenylalanine; Extrapyramidal Tracts; Female; Human | 1970 |
[Perphenazine enanthate in the treatment of chronic schizophrenia].
Topics: Adult; Chronic Disease; Female; Humans; Male; Perphenazine; Schizophrenia | 1970 |
Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background.
Topics: Acute Disease; Adult; Attention; Auditory Perception; Chlorpromazine; Chronic Disease; Dextroampheta | 1968 |
Single daily doses of neuroleptic drugs.
Topics: Chlorpromazine; Chlorprothixene; Chronic Disease; Dosage Forms; Fluphenazine; Haloperidol; Humans; M | 1969 |